ERBB2 and ductal breast carcinoma in situ: The HER2 DCIS subtype was more frequent in progressors than in non-progressors (29% vs. 17%, respectively), while Luminal A DCIS were less common in progressors (25% vs. 37%, respectively) (Supplemental Figure S5B), although differences did not reach statistical significance.